Slate Medicines’ Merger and $245M Private Placement Fuel Mission in Migraine

Migraine drugs developer Slate Medicines is going public in a reverse merger with Fulcrum Therapeutics. The biotech’s lead antibody drug blocks two novel migraine targets, offering the potential for better efficacy compared to other next-generation migraine drugs in R&D. The post Slate Medicines’ Merger and $245M Private Placement Fuel Mission in Migraine appeared first on…

Read More

The Rise of Consumer Diagnostics and Emerging Trends

Consumer diagnostics will be one of several discussions at the INVEST Digital Health conference focused on power shifting to the consumer in healthcare. The conference is scheduled for October 29 in Dallas at Pegasus Park, in partnership with Health Wildcatters. Click here to view the agenda and register. The post The Rise of Consumer Diagnostics…

Read More

Pre-Surgical Complications (Part 6) — The Decision

By MATTHEW HOLT Strap in for the tale of why your hero is spending most of his life down YouTube rabbit holes of cardiology videos while blundering his way around many many medical centers and exposing many problems with American health care even before he gets close to the operating table. Yes it’s Matthew Holt’s…

Read More